Trials / Completed
CompletedNCT03478124
Neuropsychological Evaluation for Early Diagnosis of PSP
The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini · Academic / Other
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.
Detailed description
Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive deficits are a leading feature of PSP and they actually represent one of the four functional core domains in the revised diagnostic criteria. The aim of this study is to better understand the nature of this cognitive decline, the time of its development and the relation with the other cardinal features of the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Cognitive evaluation | An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS. |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-02
- First posted
- 2018-03-27
- Last updated
- 2018-03-27
Source: ClinicalTrials.gov record NCT03478124. Inclusion in this directory is not an endorsement.